INVESTORS
Current Investors
SCP Vitalife seeks to invest in early to mid-stage life science companies with exceptional technology or other proprietary advantages that are poised to capitalize on major market trends. Over half of the Fund's investment capital is expected to go to Israeli companies with the remainder allocated to U.S. companies. Our target initial investment size is $3 – $7 million, with typical total investment of $7 – $15 million over the lifespan of the investment.
January 2010:
DEX-TD Phase I Clinical
Study initiated.
December 2009:
William Ashton joins Board
of Directors.
September 2009:
DEX-SL Phase I Clinical Study initiated in the U.S.
